NASDAQ:DBVT - DBV Technologies Stock Price, Price Target & More

$21.83 -0.24 (-1.09 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$21.83
Today's Range$21.72 - $22.28
52-Week Range$20.08 - $50.57
Volume97,526 shs
Average Volume282,012 shs
Market Capitalization$1.30 billion
P/E Ratio-8.43
Dividend YieldN/A
Beta0.98

About DBV Technologies (NASDAQ:DBVT)

DBV Technologies logoDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for Crohn's disease and respiratory syncytial virus. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Receive DBVT News and Ratings via Email

Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DBVT
CUSIPN/A
Phone33-1-55-42-78-78

Debt

Debt-to-Equity Ratio0.01%
Current Ratio4.37%
Quick Ratio4.37%

Price-To-Earnings

Trailing P/E Ratio-8.43
Forward P/E Ratio-4.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.46 million
Price / Sales92.51
Cash FlowN/A
Price / CashN/A
Book Value$2.94 per share
Price / Book7.43

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees164
Outstanding Shares57,040,000

How to Become a New Pot Stock Millionaire

DBV Technologies (NASDAQ:DBVT) Frequently Asked Questions

What is DBV Technologies' stock symbol?

DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."

How were DBV Technologies' earnings last quarter?

DBV Technologies (NASDAQ:DBVT) released its quarterly earnings data on Thursday, March, 26th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.35. View DBV Technologies' Earnings History.

What price target have analysts set for DBVT?

9 brokers have issued 1-year target prices for DBV Technologies' shares. Their forecasts range from $30.00 to $72.00. On average, they anticipate DBV Technologies' stock price to reach $48.8571 in the next year. View Analyst Ratings for DBV Technologies.

Are investors shorting DBV Technologies?

DBV Technologies saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,954,782 shares, an increase of 57.7% from the February 28th total of 1,239,316 shares. Based on an average daily volume of 306,932 shares, the days-to-cover ratio is presently 6.4 days.

Who are some of DBV Technologies' key competitors?

Who are DBV Technologies' key executives?

DBV Technologies' management team includes the folowing people:
  • Dr. Pierre-Henri Benhamou, Co-Founder, Chairman & CEO (Age 63)
  • Mr. David Schilansky, Deputy CEO & Principal Financial Officer (Age 43)
  • Mr. Bertrand Dupont, Co-Founder & CTO (Age 66)
  • Mr. Charles Ruban, Chief Operating Officer (Age 46)
  • Dr. Hugh A. Sampson, Chief Scientific Officer & Member of The Scientific Advisory Board (Age 69)

Has DBV Technologies been receiving favorable news coverage?

Headlines about DBVT stock have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DBV Technologies earned a media sentiment score of 0.10 on Accern's scale. They also gave press coverage about the company an impact score of 46.64 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are DBV Technologies' major shareholders?

DBV Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BPIFRANCE PARTICIPATIONS SA (9.90%). View Institutional Ownership Trends for DBV Technologies.

How do I buy shares of DBV Technologies?

Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DBV Technologies' stock price today?

One share of DBVT stock can currently be purchased for approximately $21.83.

How big of a company is DBV Technologies?

DBV Technologies has a market capitalization of $1.30 billion and generates $13.46 million in revenue each year. The company earns $-166,930,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. DBV Technologies employs 164 workers across the globe.

How can I contact DBV Technologies?

DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78.


MarketBeat Community Rating for DBV Technologies (DBVT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about DBV Technologies and other stocks. Vote "Outperform" if you believe DBVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DBVT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

DBV Technologies (NASDAQ:DBVT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for DBV Technologies in the last 12 months. Their average twelve-month price target is $48.8571, suggesting that the stock has a possible upside of 123.81%. The high price target for DBVT is $72.00 and the low price target for DBVT is $30.00. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.782.802.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $48.8571$48.8571$52.1429$52.1429
Price Target Upside: 123.81% upside107.37% upside128.70% upside84.12% upside

DBV Technologies (NASDAQ:DBVT) Consensus Price Target History

Price Target History for DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2018Deutsche BankSet Price TargetBuy$33.00HighView Rating Details
3/15/2018HC WainwrightReiterated RatingBuyHighView Rating Details
2/14/2018CitigroupSet Price TargetBuy$57.00LowView Rating Details
11/17/2017JMP SecuritiesInitiated CoverageOutperformN/AView Rating Details
10/31/2017Societe GeneraleUpgradeSell -> HoldN/AView Rating Details
10/23/2017BarclaysLower Price TargetOverweight$58.00 -> $30.00N/AView Rating Details
10/23/2017Morgan StanleyDowngradeOverweight -> Equal WeightN/AView Rating Details
10/23/2017Leerink SwannSet Price TargetOutperform$60.00 -> $49.00N/AView Rating Details
9/12/2017Jefferies GroupReiterated RatingBuy$51.00LowView Rating Details
2/17/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

DBV Technologies (NASDAQ:DBVT) Earnings History and Estimates Chart

Earnings by Quarter for DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT) Earnings Estimates

2018 EPS Consensus Estimate: ($4.12)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.03)($1.03)($1.03)
Q2 20181($0.98)($0.98)($0.98)
Q3 20181($1.03)($1.03)($1.03)
Q4 20181($1.08)($1.08)($1.08)

DBV Technologies (NASDAQ DBVT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2015($0.44)($0.79)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

DBV Technologies (NASDAQ:DBVT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

DBV Technologies (NASDAQ DBVT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.31%
Institutional Ownership Percentage: 39.53%
Insider Trading History for DBV Technologies (NASDAQ:DBVT)
Insider Trading History for DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ DBVT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

DBV Technologies (NASDAQ DBVT) News Headlines

Source:
DateHeadline
Head-To-Head Survey: DBV Technologies (DBVT) & The CompetitionHead-To-Head Survey: DBV Technologies (DBVT) & The Competition
www.americanbankingnews.com - April 20 at 11:08 AM
Contrasting DBV Technologies (DBVT) & Its RivalsContrasting DBV Technologies (DBVT) & Its Rivals
www.americanbankingnews.com - April 19 at 3:13 PM
DBV Technologies (DBVT) Upgraded by ValuEngine to HoldDBV Technologies (DBVT) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 18 at 4:44 PM
DBV Technologies (DBVT) Upgraded at BidaskClubDBV Technologies (DBVT) Upgraded at BidaskClub
www.americanbankingnews.com - April 16 at 10:54 AM
DBV Technologies (DBVT) Receives Average Recommendation of "Hold" from BrokeragesDBV Technologies (DBVT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 12 at 1:29 AM
Reviewing DBV Technologies (DBVT) & Its RivalsReviewing DBV Technologies (DBVT) & Its Rivals
www.americanbankingnews.com - April 8 at 11:20 PM
DBV Technologies (DBVT) PT Raised to $57.00DBV Technologies (DBVT) PT Raised to $57.00
www.americanbankingnews.com - April 8 at 3:15 PM
DBV Technologies (DBVT) Given a $49.00 Price Target by Leerink Swann AnalystsDBV Technologies (DBVT) Given a $49.00 Price Target by Leerink Swann Analysts
www.americanbankingnews.com - April 6 at 12:23 PM
DBV Technologies (DBVT) Downgraded by Zacks Investment Research to "Hold"DBV Technologies (DBVT) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 3 at 8:45 PM
DBV Technologies (DBVT) Upgraded to "Sell" by ValuEngineDBV Technologies (DBVT) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - April 3 at 4:48 PM
DBV Technologies to Attend the 11th Kempen Life Sciences ConferenceDBV Technologies to Attend the 11th Kempen Life Sciences Conference
finance.yahoo.com - April 3 at 9:59 AM
DBV Technologies (DBVT) Lifted to Buy at Zacks Investment ResearchDBV Technologies (DBVT) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM
Short Interest in DBV Technologies SA - (DBVT) Expands By 57.7%Short Interest in DBV Technologies SA - (DBVT) Expands By 57.7%
www.americanbankingnews.com - March 30 at 3:38 AM
DBV Technologies (DBVT) Upgraded to "Sell" at BidaskClubDBV Technologies (DBVT) Upgraded to "Sell" at BidaskClub
www.americanbankingnews.com - March 29 at 11:29 AM
DBV Technologies (DBVT) Downgraded by Zacks Investment ResearchDBV Technologies (DBVT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 27 at 9:44 PM
DBV Technologies (DBVT) Cut to "Hold" at BidaskClubDBV Technologies (DBVT) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 27 at 3:30 PM
DBV Technologies (DBVT) Given a $33.00 Price Target at Deutsche BankDBV Technologies (DBVT) Given a $33.00 Price Target at Deutsche Bank
www.americanbankingnews.com - March 27 at 9:31 AM
$2.77 Million in Sales Expected for DBV Technologies SA - (DBVT) This Quarter$2.77 Million in Sales Expected for DBV Technologies SA - (DBVT) This Quarter
www.americanbankingnews.com - March 27 at 7:52 AM
DBV Technologies Announces Closing of Underwriters Option to Purchase Additional Shares in Global OfferingDBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering
finance.yahoo.com - March 26 at 4:11 PM
 Analysts Expect DBV Technologies SA - (DBVT) to Post -$1.14 Earnings Per Share Analysts Expect DBV Technologies SA - (DBVT) to Post -$1.14 Earnings Per Share
www.americanbankingnews.com - March 25 at 3:13 AM
DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters Option to Purchase Additional SharesDBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - March 23 at 4:13 PM
DBV Technologies (DBVT) Announces Launch of Proposed Offering of Ordinary SharesDBV Technologies (DBVT) Announces Launch of Proposed Offering of Ordinary Shares
www.streetinsider.com - March 21 at 10:52 AM
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary SharesDBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares
finance.yahoo.com - March 20 at 4:11 PM
Head-To-Head Comparison: Acceleron Pharma (XLRN) and DBV Technologies (DBVT)Head-To-Head Comparison: Acceleron Pharma (XLRN) and DBV Technologies (DBVT)
www.americanbankingnews.com - March 19 at 7:10 PM
DBV Technologies (DBVT) "Buy" Rating Reaffirmed at HC WainwrightDBV Technologies' (DBVT) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - March 18 at 5:38 PM
DBV Technologies SA - (DBVT) Receives Consensus Rating of "Hold" from AnalystsDBV Technologies SA - (DBVT) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 18 at 1:36 AM
DBV Technologies (DBVT) Upgraded by Zacks Investment Research to HoldDBV Technologies (DBVT) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 16 at 8:21 PM
DBV Technologies Announces Filing of 2017 "Document de Référence" and 2017 Annual Report on Form 20-FDBV Technologies Announces Filing of 2017 "Document de Référence" and 2017 Annual Report on Form 20-F
finance.yahoo.com - March 16 at 5:12 PM
Equities Analysts Issue Forecasts for DBV Technologies SA -s FY2018 Earnings (DBVT)Equities Analysts Issue Forecasts for DBV Technologies SA -'s FY2018 Earnings (DBVT)
www.americanbankingnews.com - March 16 at 10:42 AM
DBV Technologies SA - (DBVT) Expected to Post FY2021 Earnings of $4.74 Per ShareDBV Technologies SA - (DBVT) Expected to Post FY2021 Earnings of $4.74 Per Share
www.americanbankingnews.com - March 15 at 2:52 PM
DBV Technologies Reports Full Year 2017 Financial ResultsDBV Technologies Reports Full Year 2017 Financial Results
finance.yahoo.com - March 14 at 5:28 PM
DBV Technologies SA. (NASDAQ:DBVT): Should The Recent Earnings Drop Worry You?DBV Technologies SA. (NASDAQ:DBVT): Should The Recent Earnings Drop Worry You?
finance.yahoo.com - March 14 at 5:28 PM
Short Interest in DBV Technologies SA - (DBVT) Increases By 28.3%Short Interest in DBV Technologies SA - (DBVT) Increases By 28.3%
www.americanbankingnews.com - March 13 at 1:40 AM
DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the CompanyDBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company
finance.yahoo.com - March 9 at 5:16 PM
 Brokerages Anticipate DBV Technologies SA - (DBVT) Will Post Quarterly Sales of $2.77 Million Brokerages Anticipate DBV Technologies SA - (DBVT) Will Post Quarterly Sales of $2.77 Million
www.americanbankingnews.com - March 9 at 2:20 AM
-$1.15 EPS Expected for DBV Technologies SA - (DBVT) This Quarter-$1.15 EPS Expected for DBV Technologies SA - (DBVT) This Quarter
www.americanbankingnews.com - March 7 at 9:14 PM
Sectoral Asset Management Inc Has $1.48 Million Stake in DBV Technologies SA - (DBVT)Sectoral Asset Management Inc Has $1.48 Million Stake in DBV Technologies SA - (DBVT)
www.americanbankingnews.com - March 6 at 2:10 PM
This Biotech Could Have A Blockbuster — Should It Partner With Big Pharma?This Biotech Could Have A Blockbuster — Should It Partner With Big Pharma?
finance.yahoo.com - March 5 at 4:51 PM
DBV Technologies SA - (DBVT) Shares Bought by Emory UniversityDBV Technologies SA - (DBVT) Shares Bought by Emory University
www.americanbankingnews.com - March 4 at 2:59 PM
DBV Technologies SA - (DBVT) Shares Bought by Hudson Bay Capital Management LPDBV Technologies SA - (DBVT) Shares Bought by Hudson Bay Capital Management LP
www.americanbankingnews.com - March 2 at 12:49 PM
Here’s What’s Important About The Latest DBV DataHere’s What’s Important About The Latest DBV Data
finance.yahoo.com - March 1 at 9:21 AM
DBV Technologies (DBVT) Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic PatientsDBV Technologies (DBVT) Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients
www.streetinsider.com - February 28 at 9:35 AM
DBV Technologies SA - (DBVT) Expected to Announce Quarterly Sales of $2.77 MillionDBV Technologies SA - (DBVT) Expected to Announce Quarterly Sales of $2.77 Million
www.americanbankingnews.com - February 21 at 11:18 AM
DBV Technologies SA - (DBVT) Receives Average Rating of "Hold" from BrokeragesDBV Technologies SA - (DBVT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 21 at 1:28 AM
BRIEF-DBV Technologies Cash And Cash Equivalents At Dec. 31 Down At 137.9 Million EurosBRIEF-DBV Technologies Cash And Cash Equivalents At Dec. 31 Down At 137.9 Million Euros
www.reuters.com - February 20 at 9:14 AM
UPDATE 2-Aimmunes peanut allergy drug meets main goal, shares surgeUPDATE 2-Aimmune's peanut allergy drug meets main goal, shares surge
www.cnbc.com - February 20 at 9:14 AM
DBV Technologies Reports December 31, 2017 Cash PositionDBV Technologies Reports December 31, 2017 Cash Position
finance.yahoo.com - February 20 at 9:14 AM
DBV Technologies (DBVT) Downgraded by BidaskClub to "Strong Sell"DBV Technologies (DBVT) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - February 19 at 3:56 PM
Citigroup Analysts Give DBV Technologies (DBVT) a $57.00 Price TargetCitigroup Analysts Give DBV Technologies (DBVT) a $57.00 Price Target
www.americanbankingnews.com - February 15 at 11:22 PM
DBV Technologies (DBVT) Says FDA Agreed that Efficacy and Safety Data for Viaskin Peanut Supports the Submission of BLADBV Technologies (DBVT) Says FDA Agreed that Efficacy and Safety Data for Viaskin Peanut Supports the Submission of BLA
www.streetinsider.com - February 15 at 8:53 AM

SEC Filings

DBV Technologies (NASDAQ:DBVT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

DBV Technologies (NASDAQ:DBVT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

DBV Technologies (NASDAQ DBVT) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.